Program 4th International Symposium

All times are in CEST. All recordings are available up to three months after the symposium.

Restricted Content

To view this protected content, enter the password below:

Day 2, Monday, 28 June 2021

16:00-16:10

Opening (live)

Restricted Content

To view this protected content, enter the password below:

16:10-17:00

SESSION I: TRANSLATIONAL BIOLOGY

Chairs: Ralf Küppers, Essen/DE; Megan Lim, Philadelphia PA/USA

16:10

Single cell RNA-sequencing of the Hodgkin lymphoma tumor microenvironment
Christian Steidl, Vancouver/CAN

Restricted Content

To view this protected content, enter the password below:

16:30

Genetics of classic Hodgkin lymphoma
Enrico Tiacci, Perugia/IT

Restricted Content

To view this protected content, enter the password below:

16:50

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

17:00

Break

17:05-17:45

TRANSLATIONAL BIOLOGY

Oral Abstract Presentation

17:05

Genomic Landscape of Reed-Sternberg Cells of Hodgkin Lymphoma from Children, Adolescents, and Young Adults

M. Roshal, J. Z. Xiang, S. Park, M. Oberley, E. Ruchdeschel, M. Lim, G. Wertheim, M. Barth, T. M. Horton, B. Bhinder, K. Wha Eng, F. He, W. Zhang, A. Tan, O. Elemento, L. Giulino-Roth

Restricted Content

To view this protected content, enter the password below:

17:15

CRISPR/Cas9-mediated knockout reveals important role of CD30 in classical Hodgkin lymphoma cell lines

A. L. Weiß, A. Lollies, M. A. Weniger, R. Küppers

Restricted Content

To view this protected content, enter the password below:

17:25

KIR B haplotype modulates susceptibility to cHL in an EBV dependent manner

P. Jiang, M. Stulp, B. Hepkema, I. Nolte, A. van den Berg, A. Diepstra

Restricted Content

To view this protected content, enter the password below:

17:35

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

17:45

Break

18:00-18:55

SESSION II: IMMUNE CHECKPOINT INHIBITION

Chairs: Peter Cole, New Jersey/USA; Stefan Gattenlöhner, Gießen/DE

18:00

T cells in the Hodgkin lymphoma microenvironment: implications for immune checkpoint inhibition
Arjan Diepstra, Groningen/NL

Restricted Content

To view this protected content, enter the password below:

18:20

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

18:30

Break

18:35-19:25

IMMUNE CHECKPOINT INHIBITION

Oral Abstract Presentation

18:35

Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

J. Hochberg, J. Basso, L. Klejmont, A. Flower, K. Bortfeld, L. Harrison, Q. Shi, H. Islam, P. Gerard, S. Voss, M. Cairo

Restricted Content

To view this protected content, enter the password below:

18:45

Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667

C. Mauz-Korholz, S. Daw, M. Mascarin, A. Fernandez-Teijeiro, K. Kelly, F. Keller, E. Kim, A. Nahar, P. Marinello, B. Hoppe, L. Giulino-Roth

Restricted Content

To view this protected content, enter the password below:

18:55

Elucidating cell-cell interactions in pediatric and adolescent Hodgkin Lymphoma for targeted therapy by single cell RNA sequencing

J. K. de Kanter, A. M. Brandsma, T. Margaritis, A. Beishuizen, M. Scheijde-Vermeulen, R. van Boxtel, F. Meyer-Wentrup

Restricted Content

To view this protected content, enter the password below:

19:05

A randomized Phase III trial of Brentuximab vedotin (Bv) for de novo High-Risk Classical Hodgkin Lymphoma (cHL) in children and adolescents – Study Design and Incorporation of secondary endpoints in Children’s Oncology Group (COG) AHOD1331.

S. M. Castellino, S. K. Parsons, Q. Pei, K. McCarten, S. Kessel, A. Punnett, T. M. Horton, T. O. Henderson, D. Hodgson, H. Dave, A. – M. Charpentier, F. G. Keller, K. M. Kelly

Restricted Content

To view this protected content, enter the password below:

19:15

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

Day 3, Tuesday, 29 June 2021

16:00-17:10

SESSION III: GLOBAL EXPERIENCES

Chairs: Mario de Paula, Barretos/BR; Leanne Super, Melbourne/AU

16:00

Evolution of CLEHOP as a Cooperative Group and its Experience with the Latin American LH Protocol
David Veron, Buenos Aires/BR

Restricted Content

To view this protected content, enter the password below:

16:20

Hodgkin lymphoma: Trials and tribulations in a middle income country. The first inclusive prospective paediatric cancer study in South Africa
Jennifer Geel, Johannesburg/ZA

Restricted Content

To view this protected content, enter the password below:

16:40

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

16:50

Interactive Case Presentation (live)

Restricted Content

To view this protected content, enter the password below:

17:10

Break

17:15-17:55

GLOBAL EXPERIENCES

Oral Abstract Presentation

17:15

Epstein Barr Virus in children and adolescents with classical Hodgkin Lymphoma: analysis of a cohort of 299 patients

V. Pereira1, S. Boudjemaa2, C. Besson3, P. Simon1, T. Leblanc4, J. Landman-Parker5, 6

Restricted Content

To view this protected content, enter the password below:

17:25

High response rate to combined chemotherapy avoiding radiotherapy in children and adolescents with classical Hodgkin lymphoma. Preliminary results of GALOP LH 2017 Protocol.

E. M. Alfaro, M. Schelotto, M. Guitter, C. Sanchez, L. Peruzzo, C. Pennella, M. S. Felice, A. Dabezies, L. Castillo, P. Zubizarreta

Restricted Content

To view this protected content, enter the password below:

17:35

The GATLA (Argentinian Collaborative Group) experience through international cooperation in Pediatric Hodgkin Lymphoma (HL)

D. Veron, P. Streitenberger, D. Freigeiro, M. Castellanos, M. Metzger

Restricted Content

To view this protected content, enter the password below:

17:45

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

17:55

Break

18:10-19:00

SESSION IV: INTERNATIONAL TRIAL WORKSHOP

Chairs: Mitchell Cairo, New York/USA; Dieter Körholz, Gießen/DE

18:10

Global nLPHL trial proposal
Michael Binkley, Stanford, CA/USA; Jamie Flerlage, Memphis, TN/USA

Restricted Content

To view this protected content, enter the password below:

18:30

ARIA Guide: a Comprehensive tool for the management of Childhood Cancer
Nikhill Bhakta, Memphis TN/USA

Restricted Content

To view this protected content, enter the password below:

18:50

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

19:00

Break

19:05

Günther Schellong Award Ceremony

Restricted Content

To view this protected content, enter the password below:

Restricted Content

To view this protected content, enter the password below:

Restricted Content

To view this protected content, enter the password below:

Restricted Content

To view this protected content, enter the password below:

19:05-20:00

Interactive Case Presentation, Meet the Experts

19:15

Content

Day 4, Wednesday, 30 June 2021

16:00-16:50

SESSION V: RELAPSE TREATMENTS

Chairs: Stephen Daw, London/UK; Kara Kelly, Buffalo, NY/USA

16:00

Precision Medicine for Hodgkin Lymphoma
Lisa Giuliano Roth, New York/USA

Restricted Content

To view this protected content, enter the password below:

16:20

Risk and Response adapted salvage treatments inR/R Classical HL in children and young people – European guidelines
Stephen Daw, London/UK

Restricted Content

To view this protected content, enter the password below:

16:40

Panel discussion (live)
Panel members: Stephen Daw, London/UK; Karin Dieckmann, Vienna/AT; Kara Kelly, Buffalo, NY/USA;
Thierry Leblanc, Paris/FR

Restricted Content

To view this protected content, enter the password below:

16:50

Break

16:55

Interactive Case Presentation (live)

Restricted Content

To view this protected content, enter the password below:

17:30-17:45

RELAPSE TREATMENTS

Oral Abstract Presentation

17:30

The addition of bendamustine to Brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single centre series

A. McMillan1, A. T. O’Neill1, W. Townsend1, J. Lambert1, A. Virchis1, R. Shah2, L. Menezes3, P. Humphries3, K. Von Both2, V. Grandage4, R. Hough4, B. Carpenter4, K. M. Ardeshna1, S. Daw4

Restricted Content

To view this protected content, enter the password below:

17:40

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

17:45

Break

18:00-20:00

SESSION VI: CELLULAR THERAPIES

Chairs: Cathrine Bollard, Washington D.C./USA; Birgit Burkhardt, Münster/DE

18:00

T cell therapies to overcome the tumor microenvironment in HL
Cathrine Bollard, Washington D.C./USA

Restricted Content

To view this protected content, enter the password below:

18:20

CD30 CAR T for HL and ALCL
Barbara Savoldo, Houston, TX/USA

Restricted Content

To view this protected content, enter the password below:

18:40

Study on Immunodeficiencies & EBV-induced HL
Sylvain Latour, Paris/FR

Restricted Content

To view this protected content, enter the password below:

19:00

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

19:10

Interactive Case Presentation, Meet the Experts (live)

Restricted Content

To view this protected content, enter the password below:

19:15-20:15

Interactive Case Presentation, Meet the Experts

19:15

Content

Day 5, Thursday, 1 July 2021

16:00-17:15

SESSION VII: CONTEMPORARY RADIOTHERAPY

Chairs: Karin Dieckmann, Vienna/AT; Brad Hoppe, Jacksonville, FL/USA

16:00

Panel Case Discussion (Intermediate risk)

Emphasis on field design
Maurizio Mascarin, Aviano/IT (EuroNet)
David Hodgson, Toronto/CAN (COG)
Matthew Krasin, Memphis, TN/USA (St. Jude/Stanford/Havard)

Questions

Cardiac/breast toxicity
Louis (Sandy) Constine, Rochester/USA

Restricted Content

To view this protected content, enter the password below:

Restricted Content

To view this protected content, enter the password below:

Restricted Content

To view this protected content, enter the password below:

17:00

Q&A

Restricted Content

To view this protected content, enter the password below:

17:15

Break

17:20-17:50

CONTEMPORARY RADIOTHERAPY

Oral Abstract Presentation

17:20

Reduction in Cardiac Radiation Dose Among Children Receiving Mediastinal RT: Comparison of Involved-Site vs Involved-Field RT Delivered in Three Children’s Oncology Group Trials.

S. Bergeron Gravel1, M. Khandwala2, S. L. Wolden3, S. M. Castellino4, D. L. Friedman5, K. M. Kelly6, K. B. Roberts7, L. S. Constine8, C. L. Schwartz9, T. J. Fitzgerald10, B. S. Hoppe11, D. Hodgson12

Restricted Content

To view this protected content, enter the password below:

17:30

Cost-effectiveness of proton therapy for young adults with mediastinal lymphoma: analysis of an institutional cohort

R. B. Mailhot Vega, S. Patel, J. E. Bates, J. Lynch, M. Bansal, W. Slayton, S. K. Parsons, B. S. Hoppe, N. P. Mendenhall

Restricted Content

To view this protected content, enter the password below:

17:40

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

17:50

Break

18:05-19:20

SESSION VIII: SURVIVORSHIP AND AFTERCARE

Chairs: Melissa Hudson, Memphis, TN/USA; Hamish Wallace, Edinburgh/UK

18:05

Fertility preservation
Hamish Wallace, Edinburgh/UK

Restricted Content

To view this protected content, enter the password below:

18:25

Late Health Outcomes after Childhood, Adolescent, and Young Adult Hodgkin Lymphoma
Matthew Ehrhardt, Memphis, TN/USA

Restricted Content

To view this protected content, enter the password below:

18:45

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

18:55

Interactive Case Presentation, Meet the Experts (live)

Restricted Content

To view this protected content, enter the password below:

19:20

Break

19:25-20:05

SURVIVORSHIP AND AFTERCARE

Oral Abstract Presentation

19:25

Subsequent Malignant Neoplasms Among Children and Adolescents with Hodgkin Lymphoma Treated with Response-Adapted Therapy: A Report from the Children’s Oncology Group Study AHOD0031

L. Giulino-Roth, Q. Pei, A. Buxton, R. Bush, S. L. Wolden, L. S. Constine, K. M. Kelly, C. L. Schwartz, D. L. Friedman

Restricted Content

To view this protected content, enter the password below:

19:35

Late effects after Hodgkin lymphoma in childhood and adolescence – results of the German Survivor Cohort after 22 years of follow-up

U. Hennewig, A. Schneider, S. Mann, D. Körholz, C. Mauz-Körholz

Restricted Content

To view this protected content, enter the password below:

19:45

Hyperlipoproteinemia, insulin resistance and metabolic syndrome in long-term survivors of Hodgkin lymphoma during childhood and adolescence

M. Cepelova, J. Kruseova, A. Luks, V. Capek, P. Cepela, J. Potockova, P. Kraml

Restricted Content

To view this protected content, enter the password below:

19:55

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

Day 6, Friday, 2 July 2021

16:00-16:55

SESSION IX: SEARCH FOR CAYAHL

Chairs: Jamie Flerlage, Memphis TN/USA; Dietrich Stoevesandt, Halle/DE

16:00

„E“ Lesions of Lung – Imaging Update
Kathleen McCarten, Providence, RI/USA

Restricted Content

To view this protected content, enter the password below:

16:20

Imaging for Hodgkin Lymphoma
Henrique Lederman, Sao Paolo/BR

Restricted Content

To view this protected content, enter the password below:

16:40

Q&A – Discussion on Future Plans (live)

Restricted Content

To view this protected content, enter the password below:

16:55

Break

17:00-17:40

SEARCH FOR CAYAHL

Oral Abstract Presentation

17:00

Methodological comparison of volumetric analysis on FDG PET in pediatric Hodgkin Lymphoma assessed at different timing

E. Lopci1, C. Elia2, A. Piccardo3, A. Castello1, E. Borsatti5, P. Zucchetta6, A. Cistaro3, R. Burnelli4, M. Mascarin2

Restricted Content

To view this protected content, enter the password below:

17:10

The impact of the Point-spread-function (PSF) reconstruction on the response assessment in the Interim-PET (iPET) in Hodgkin lymphoma (HL)

T. W. Georgi, L. Kurch, D. Hasenclever, D. Körholz, O. Sabri, R. Kluge, C. Mauz-Körholz

Restricted Content

To view this protected content, enter the password below:

17:20

Impact of central review of imaging in an FDG-PET response adapted Pediatric Hodgkin lymphoma protocol

B. S. Hoppe, S. M. Castellino, S. Kessel, A. Alazraki, S. Voss, J. Mhlanga, H. Lai, E. Eutsler, F. G. Keller, K. M. Kelly, S. Cho, K. McCarten

Restricted Content

To view this protected content, enter the password below:

17:30

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

17:40

Break

17:45-18:50

SESSION X: AYA SESSION incl. Oral Abstract Presentation

Chairs: David Hodgson, Toronto/CAN; Maurizio Mascarin, Aviano/IT

17:45

HL biology in adolscents and young adults
Anja Mottok, Ulm/DE

Restricted Content

To view this protected content, enter the password below:

18:05

Simulation modelling to delineate long term patient outcome in AYA HL
Susan Parsons, Boston, MA/USA

Restricted Content

To view this protected content, enter the password below:

18:25

Outcomes by age in pediatric and adolescent patients treated for de novo Hodgkin lymphoma on contemporary Children’s Oncology Group trials

J. M. Kahn, K. M. Kelly, Q. Pei, D. L. Friedman, F. G. Keller, S. Bhatia, T. O. Henderson, C. L. Schwartz, S. M. Castellino

Restricted Content

To view this protected content, enter the password below:

18:35

Q&A (live)

Restricted Content

To view this protected content, enter the password below:

18:50

Break

19:00-19:30

AWARD SESSIONS AND CLOSE OUT

19:00

Poster Award Session (live)

Restricted Content

To view this protected content, enter the password below:

19:15

Conclusion of 4-ISCAYAHL (live)
Christine Mauz-Körholz, Gießen/DE; Monika Metzger, Memphis, TN/USA
Setting Goals for the Next Meeting

See you 2023 in Memphis/TN USA

Restricted Content

To view this protected content, enter the password below:

available all days

Recorded Poster presentation

Prognostic Value of Interim and End of Treatment PET-CT Scan Results in Pediatric Hodgkin Lymphoma

M. Abdelhalim, O. Zahra, N. El-Deeb, S. Fadel

Circulating tumor DNA in Genetic Profiling and Monitoring of Pediatric Hodgkin Lymphoma

R. Shyam1, D. Kurtz2, S. Alig2, M. Jin2, M. Link1, L. Marks1, A. Alizadeh2

Restricted Content

To view this protected content, enter the password below:

An Intergroup Approach for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826.

S. M. Castellino, M. LeBlanc, A. Herrera, S. K. Parsons, A. Punnett, D. Hodgson, S. Rutherford, N. Kahn, L. S. Constine, K. Davison, A. Prica, J. Friedberg, K. M. Kelly

Restricted Content

To view this protected content, enter the password below:

Cardiac substructures dose sparing in pediatric Hodgkin’s lymphoma

I. Iamundo De Cumis, I. Solla, M. A. Deidda, R. Mura, R. Farigu, M. Mascarin, R. Barbara

Restricted Content

To view this protected content, enter the password below:

3′ untranslated region A>C (rs3212227) polymorphism of Interleukin 12B gene as a potential risk factor for Hodgkin’s lymphoma in Brazilian children and adolescents

B. O. Silva, A. N. Correia, T. F. Barros, L. P. O. Lima, A. L. Morais, R. Hassan, E. Dellalibera, M. D. S. M. Cavalcanti, M. T. C. Muniz

Restricted Content

To view this protected content, enter the password below:

Assessment of tumor antigen specific T cell immunity and cytokine milieu at diagnosis in patients with high risk Hodgkin Lymphoma treated on Children’s Oncology Group trial AHOD1331

H. Dave, T. M. Horton, M. Mai, D. Saunders, G. Jenkins, Q. Pei, F. G. Keller, S. M. Castellino, K. M. Kelly, C. Bollard

Restricted Content

To view this protected content, enter the password below:

Comparative proteomic profiling in recurrent pediatric/adolescent Hodgkin Lymphoma

O. Repetto, L. Mussolin, C. Elia, L. Caggiari, M. De Zorzi, A. Garbin, C. Diamanti, I. Gallingani, M. Bianchi, S. Buffardi, A. Sala, R. Burnelli, E. Facchini, M. Mascarin, V. De Re

Restricted Content

To view this protected content, enter the password below:

Nodular Lymphocyte Predominant Hodgkin Lymphoma – experience of Polish Pediatric Leukemia/Lymphoma Study Group

T. Klekawka, A. Moryl-Bujakowska, K. Smalisz, A. Brozyna, J. Kwasnicka, R. Chaber, I. Ruranska, A. Wziatek, M. Mitura-Lesiuk, T. Stachowicz-Stencel, A. Koltan, K. Muszynska-Roslan, M. Stolarska, A. Mizia-Malarz, M. Woszczyk, A. Urbanek-Dadela, B. Przybyszewski, K. Zielezinska, W. Balwierz

Restricted Content

To view this protected content, enter the password below:

Real-life experience of multisciplinary pediatric lymphoma tumor board: decision’s impact on Hodgkin Lymphoma treatment choice and results

A. Potier, F. Montravers, H. Ducou Le Pointe, T. Leblanc, H. Pacquement, L. Brugieres, C. Rigaud, M. – E. Dourthe, P. Brice, V. Martin, S. Boudjemaa, S. Helfre, J. Landman-Parker

Restricted Content

To view this protected content, enter the password below:

Result of therapy for Hodgkin Lymphoma (HL): a report from the Chilean pediatric National Cancer Program (PINDA)

E. Concha, M. Cordova, A. Becker, C. Rizzardini, C. Salgado, V. Perez, E. Fernandez, F. Espinoza, P. Martinez, M. Valero, L. Neira, M. Arriagada

Restricted Content

To view this protected content, enter the password below:

Expression of human endogenous retroviruses and associated transcripts in Hodgkin lymphoma cells

K. Engel, A. Krüger, V. Vandrey, J. Schneider, I. Volkmer, A. Emmer, M. S. Staege

Restricted Content

To view this protected content, enter the password below:

BV-DHAP as salvage treatment for high risk adolescent Hodgkin lymphoma

P. Muggeo, R. Angarano, R. M. Daniele, G. Ingravallo, N. Santoro

Restricted Content

To view this protected content, enter the password below:

Brentuximab vedotin (BV) in recurrent and refractory Hodgkin Lymphoma (HL) in children. Experience of Polish Pediatric Leukemia/Lymphoma Study Group

T. Klekawka, A. Moryl-Bujakowska, K. Smalisz, J. Kwasnicka, R. Chaber, A. Wziatek, T. Stachowicz-Stencel, A. Brozyna, A. Koltan, M. Stolarska, B. Przybyszewski, K. Zielezinska, W. Balwierz

Restricted Content

To view this protected content, enter the password below:

Pediatric lymphocyte-predominant Hodgkin lymphoma: Review of Spanish patients between November-2007 and October-2019

A. I. Carboné, M. Garcia, C. Bárcena, M. Guibelalde, J. L. Vivanco, C. Garrido, A. Echebarria, M. Coronado, A. Fernández-Teijeiro

Restricted Content

To view this protected content, enter the password below:

Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma

Y. Koga, M. Sekimizu, A. Iguchi, A. Kada, A. Sait, R. Asada, T. Mori, K. Horibe

Restricted Content

To view this protected content, enter the password below:

A specific chromatin structure and increased RUNX3 expression contribute to the Hodgkin/Reed-Sternberg cell-specific phenotype

T. Jox, T. Zimmermann, M. Bartkuhn, A. Bräuninger, S. Gattenlöhner, D. Körholz

Restricted Content

To view this protected content, enter the password below:

Hyperthyroidism as late adverse effect of treatment for Hodgkin lymphoma

D. Hori, R. Kobayashi, S. Matsushima, M. Yanagi, K. Kodama, D. Suzuki, K. Kobayashi

Restricted Content

To view this protected content, enter the password below:

Anemia: frequency and type in pediatric patients with Hodgkin’s lymphoma

M. L. Oscanoa Gutierrez, C. Rivera, A. Yabar

Restricted Content

To view this protected content, enter the password below:

Prognostic model for pediatric Hodgkin Lymphoma patients in developing country

E. F. de Azevedo, T. B. S. Tenório, R. S. Almeida, G. T. N. Diniz, F. Pedrosa, N. Lucena-Silva

Restricted Content

To view this protected content, enter the password below:

Outcome of Pediatric Relapsed/Refractory Hodgkin Lymphoma Patients in 2 different Latin American Settings: AHOPCA (Asociación de Hemato-Oncología Pediátrica de Centro América) and GATLA (Grupo Argentino de Tratamiento de Leucemia Aguda)

D. Veron, P. Streitenberger, M. Castellanos, J. Blanco, P. de Alarcon, M. Metzger

Restricted Content

To view this protected content, enter the password below:

Is it Possible to Work together in Latin America? The Latin American Consortium (CLEHOP) experience with Hodgkin Lymphoma (HL)Outcome of Pediatric Relapsed/Refractory Hodgkin Lymphoma Patients in 2 different Latin American Settings: AHOPCA (Asociación de Hemato-Oncología Pediátrica de Centro América) and GATLA (Grupo Argentino de Tratamiento de Leucemia Aguda)

D. Veron, M. Castellanos, A. Arancibia, M. de Paula, P. de Alarcon, M. Metzger

Restricted Content

To view this protected content, enter the password below:

Better outcome of children with newly-diagnosed classical Hodgkin’s lymphoma treated with PET response-guided treatment in Taiwan: A single center experience

S. – H. Chen, C. Lin, C. – P. Yang, T. – H. Jaing, C. – K. Tseng, T. – Y. Chang, W. – H. Kao, C. Hsueh, I. – J. Hung

Restricted Content

To view this protected content, enter the password below:

Expression of splice variants of the transcription factor ONECUT2 in Hodgkin lymphoma cells

P. Lein, I. Volkmer, M. S. Staege

Restricted Content

To view this protected content, enter the password below:

Outcomes after initial refusal of curative treatment in patients with Hodgkin lymphoma in British Columbia

M. Chahal, A. Jiang, A. Hayden, K. Savage, D. Villa, D. Scott, A. Gerrie, A. Lo, M. Chan, T. Pickles, J. Connors, L. Sehn, C. Freeman

Restricted Content

To view this protected content, enter the password below:

CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype

J. Veldman, J. Rodrigues Plaça, L. Chong, M. M. Terpstra, M. Mastik, L. van Kempen, T. Aoki, C. Steidl, A. van den Berg, L. Visser, A. Diepstra

Restricted Content

To view this protected content, enter the password below:

Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma

E. A. M. Zijtregtop, W. – C. Wong, R. Hoogendijk, A. Thano, C. M. Zwaan, F. Meyer-Wentrup, A. Beishuizen

Restricted Content

To view this protected content, enter the password below:

Clinical trial of Pediatric Hodgkin Lymphoma in Japan and Next Trial Plan

M. Kamei, Y. Koga, R. Fukano, K. Oki, T. Mori, A. Nakazawa, M. Tanaka, T. Tsuchimochi, D. Hori, N. Fujita, T. Mitui, T. Mori, R. Kobayashi

Restricted Content

To view this protected content, enter the password below:

Immunologic dysfunction and Hodgkin Lymphoma: two sides of a coin?

R. Rana, P. Muggeo, R. M. Daniele, G. Arcamone, M. Grassi, R. Angarano, N. Santoro

Restricted Content

To view this protected content, enter the password below:

Long-term-survival of pediatric Hodgkin lymphoma (HL) patients after GPOH-HD 2002 study treatment

K. A. Rozwod, U. Hennewig, A. Schneider, A. Ismail, S. Avondstondt, D. Körholz, C. Mauz-Körholz

Restricted Content

To view this protected content, enter the password below:

Conference days

Download